NEW YORK (GenomeWeb News) – Epigenomics today said that it has established a Level 1 American Depositary Receipt program enabling the firm to trade publicly in the US.

The Berlin, Germany-based molecular diagnostics firm said that its ADRs are US dollar-negotiable certificates that represent ordinary shares of the company at a ratio of five ordinary shares to one Epigenomics ADR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.